Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY23 Earnings Presentation
17 slides from Ngl Fine-chem's earnings presentation, August 2022
Slide 1: Earnings Presentation Q1 22-23
Earnings Presentation Q1 22-23
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by NGL Fine-Chem Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 3: Q1/FY23 Highlights of the Year
Q1/FY23 Highlights of the Year 3
Slide 4: Year in review
Year in review Business Environment Operations Demand in key markets subdued during Q1 22-23, however Subdued demand witnessed during the year in Anthelmentics customer retention still high and Antiparasitics, top 5 products saw reduction in demand •Macro factors pushed input costs to new highs duri
Slide 5: Consolidated profit & loss statement
Consolidated profit & loss statement Rupees lakhs Q1 22-23 Q4 21-22 Change Q1 21-22 Revenue Income 67.75 87.04 -22.16% 80.41 Cost of Material Consumed 35.24 39.93 32.26 Gross Profit 32.51 47.11 -30.99% 48.15 Gross Profit Margin (%) 48.0% 54.1% 59.9% Employee Expenses 8.90 9.27 7.46 Other Expenses 18
Slide 6: Segment distribution
Segment distribution Q1 FY23 Revenue Distribution Q1 22-23 Rupees Crores Q1 22-23 Q1 21-22 Change Q4 21 -22 HUMAN API FORMULATIONS 5% VET API 55.41 57.51 -3.79% 66.19 4% OTHERS 1.94 12.73 -556.19% 4.22 OTHERS HUMAN API 2.62 3.26 -24.43% 6.65 3% FORMULATIONS 2.76 2.99 -8.33% 1.06 VET API 88% VET API
Slide 7: Regional distribution
Regional distribution Q1 22-23 Revenue Distribution ROW USA 0% Revenue (Rs Cr) Q1 22-23 Q4 21-22 Change FY 22 15% Asia 22.6 19.0 19% 93.8 Asia Europe 15.8 22.0 -28% 87.2 35% India 16.5 23.2 -29% 76.3 ROW 9.5 8.5 12% 47.2 USA 0.1 3.1 -98% 9.8 India 26% Europe 24% Asia Europe India ROW USA 7
Slide 8: Overview, Key Strengths and Strategy
Overview, Key Strengths and Strategy 8
Slide 9: Leading animal health company
Leading animal health company Comprehensive product 24 APIs (22 veterinary API, 2 human), 4 intermediates, 10 finished dosage forms portfolio Best quality and value-driven pricing Market leadership in Leadership in top 5 products – 50%+ market share vet API Growing position in next 4 – takin
Slide 10: Leadership in veterinary API segment
Leadership in veterinary API segment Strong controls of processes with Wide Range of Product Categories High quality and reliable 95% in-house manufacturing and products with no market rejection Anthelmintics backward integrated facilities in 15 years leading to cost competitiveness Ectoparasiticide
Slide 11: State-of-the-art manufacturing capabilities
State-of-the-art manufacturing capabilities 3 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities 10,000 m2 102 m3 194 m3 Area of manufacturing Glass-lined reactors S
Slide 12: Advantageously placed in a growing opportunity
Advantageously placed in a growing opportunity Market Size 2020 Market Size 2027 Segment Trends Growth Drivers Pharma segment to grow Rising prevalence of at higher rate – 5.4% Animal Health zoonotic diseases, animal $192 Billion CAGR Market $139 Billion (CAGR – 4.7%) population & pet ownership
Slide 13: Strategy for next leg of growth
Strategy for next leg of growth Brownfield Expansion Outsource Production De-bottlenecking Ongoing initiatives to increase capacities to • Completed 26 cr expansion in • Target to outsource production • Continuous debottlenecking & meet growing demand subsidiary Macrotech to 15% by FY24 process impr
Slide 14: Historical Financial Performance
Historical Financial Performance 14
Slide 15: Robust financial performance
Robust financial performance Consolidated Figures Revenue (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 27% CAGR 28% CAGR 35% CAGR 318 80 57 50 258 68 153 152 32 20 19 8 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) 59% 58% 60% 54% 31% 21% 21% 22%
Slide 16: Improving efficiencies
Improving efficiencies Consolidated Figures ROCE (%) Debt/ Equity (x) Fixed Asset Turnover (x) 53% 3.4 3.4 0.25 0.23 2.5 34% 2.3 27% 0.13 0.07 12% FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 ROCE = EBIT / Avg Capital Employed (Shareholder’s Fund + Total Debt) Debt/Equity = Total Debt
Slide 17: Thank You
Thank You NGL Fine-Chem Ltd Pallavi Pednekar (Company Secretary) cs@nglfinechem.com 17